Cough

Singaporeans are Armouring Up Against Viral Infections and Diseases with LAC's Immunity Arsenal

Retrieved on: 
Monday, March 4, 2024

In Singapore, while most citizens have established "the new normal", the upward trend of COVID-19 is still a pressing issue.

Key Points: 
  • In Singapore, while most citizens have established "the new normal", the upward trend of COVID-19 is still a pressing issue.
  • Occurrences of Tuberculosis have also been regular, with active cases constantly being detected through the country's National TB Programme.
  • The pressing issue about contracting such respiratory diseases is the lasting effects that it creates, even after the patient has recovered.
  • The possibilities of patients having recurring illnesses when their immunity weakens also poses a potential threat to the nation's overall wellbeing.

ImmunoLytics: Plan Ahead for Spring Allergy Season

Retrieved on: 
Thursday, February 29, 2024

Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.

Key Points: 
  • Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.
  • If allergy sufferers also have mold sensitivity, that will exacerbate the situation.
  • To better prepare for the upcoming spring allergy season, people should test their homes to see if there is a mold issue.
  • ImmunoLytics Mold Check-Up™ costs $36 per room and is analyzed by the company’s lab team that looks for 37,000 species of mold.

Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence

Retrieved on: 
Tuesday, February 27, 2024

The study fulfilled its primary aim of demonstrating safety and feasibility of Amber’s new surgical procedure, validating a scalable approach to accurately implant two electrode leads on the pudendal nerve.

Key Points: 
  • The study fulfilled its primary aim of demonstrating safety and feasibility of Amber’s new surgical procedure, validating a scalable approach to accurately implant two electrode leads on the pudendal nerve.
  • Clinically significant improvements in symptom-related quality-of-life were observed in both mixed and refractory urge UI patients.
  • In patients with mixed UI, this was manifest as reductions in both stress and urge incontinence events.
  • The study also demonstrated the utility of patient-controlled adaptive algorithms using Amber-UI’s integrated sensors.

Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development

Retrieved on: 
Monday, March 4, 2024

Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.

Key Points: 
  • Nocion Therapeutics, a clinical-stage biopharmaceutical company, today announced that it has raised $62 million in Series B funding.
  • Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
  • With this financing, Nocion has raised $122 million since the company was founded in 2018.
  • “We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease,” said Dr. Richard Batycky, Chief Executive Officer of Nocion.

New Two-Year Results Show Sustained Improvement in Chronic Rhinitis Symptoms Following a Single Procedure with Aerin Medical’s RhinAer®

Retrieved on: 
Thursday, February 29, 2024

These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.

Key Points: 
  • These results demonstrate the durable treatment effect of RhinAer® for treating chronic rhinitis, showing a significant improvement in symptoms through two years.
  • These findings build on the previously published results of two separate studies that also demonstrated significant, sustained improvement with RhinAer treatment.1,2
    This press release features multimedia.
  • More than 87% of patients responded to treatment and patients showed sustained improvement in chronic rhinitis symptoms at two years.
  • Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat and may significantly lower a person’s quality of life.

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Monday, February 19, 2024

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

MUCINEX LAUNCHES "THE MUCUS MASHER," A FIRST OF ITS KIND GAMING EXPERIENCE BY AN OTC BRAND THAT LETS CONSUMERS CRUSH MR. MUCUS

Retrieved on: 
Tuesday, February 27, 2024

PARSIPPANY, N.J., Feb. 27, 2024 /PRNewswire/ -- When you're sick with a cold or flu, you're desperate to find something—anything—to crush those pesky symptoms and get on with your day.

Key Points: 
  • That's why Mucinex, a Reckitt brand and the #1 most trusted brand by physicians for cough and cold symptoms*, is announcing the launch of the Mucus Masher, a brand-new, first-of-its-kind online gaming experience that uses state-of-the-art A.I.
  • Launching February 26th at MucusMasher.com , this addictive, snot-busting game lets consumers crush the iconic Mucinex mascot Mr. Mucus, the notorious humanoid blob and epitome of coughs, colds, and congestion.
  • Mucinex has a sneaky stunt up its sleeve to drive awareness of "Mucus Masher," so be sure to keep your eyes peeled.
  • You can stop by Walmart, Target, your local pharmacy, or nearest food retailer to buy Mucinex.

Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test

Retrieved on: 
Tuesday, February 27, 2024

CLEVELAND, Feb. 27, 2024 /PRNewswire/ -- Reese Pharmaceutical is expanding its over-the-counter (OTC) diagnostic portfolio with the launch of ColoTest®, an at-home Fecal Immunochemical Test (FIT) that identifies the presence of hidden blood in the stool in support of the early detection of colon cancer or gastrointestinal disorders such as colitis, diverticulitis, and polyps.

Key Points: 
  • A recent report by the American Cancer Society revealed a troubling spike in new colon and rectal cancer diagnoses across the US.
  • "90% of colon cancer-related deaths are thought to be preventable if caught early, and yet more than 29 million Americans are not screening for it.
  • With colon cancer rates on the rise, it is more important than ever for people to be proactive.
  • This test is performed in the comfort of your own home with results at home as soon as 1 minute," said Jeffrey Reese, President, of Reese Pharmaceutical.

Waycen and MegaMind Sign AI Endoscopy supply Agreement to Medical market in the Middle East

Retrieved on: 
Monday, February 19, 2024

Through this agreement, Waycen will leverage MegaMind IT Solution's extensive network in the Middle East healthcare market to introduce its artificial intelligence gastrointestinal endoscopy software 'WAYMED Endo' and AI respiratory self-screening service 'WAYMED Cough.'

Key Points: 
  • Through this agreement, Waycen will leverage MegaMind IT Solution's extensive network in the Middle East healthcare market to introduce its artificial intelligence gastrointestinal endoscopy software 'WAYMED Endo' and AI respiratory self-screening service 'WAYMED Cough.'
  • This collaboration aims to solidify Waycen's presence in the Middle East medical market.
  • MegaMind, IT Solution a specialized company located in Saudi Arabia, owns 13 group hospitals within the Middle East region.
  • Hamza Batterjee, the CEO of MegaMind, expressed his confidence in the agreement, saying, " MegaMind has a mission and confidence to lead digital innovation in the Middle East healthcare market."

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
Wednesday, February 14, 2024

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.